{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:13:22Z","timestamp":1758636802683,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The ZEUS study was funded by Novartis Pharma GmbH, Nuernberg, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12882-018-0950-1","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T07:39:28Z","timestamp":1530171568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study"],"prefix":"10.1186","volume":"19","author":[{"name":"on behalf of the ZEUS Study Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-6933","authenticated-orcid":false,"given":"Ute","family":"Eisenberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Sommerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf P.","family":"W\u00fcthrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Suwelack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"M\u00fchlfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingeborg A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Nadalin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Porstner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Arns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"issue":"9800","key":"950_CR1","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)60699-5","volume":"378","author":"BJ Nankivell","year":"2011","unstructured":"Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet. 2011;378(9800):1428\u201337.","journal-title":"Lancet"},{"issue":"2","key":"950_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1097\/00007890-199401001-00009","volume":"57","author":"DN Rush","year":"1994","unstructured":"Rush DN, Henry SF, Jeffery JR, Schroeder TJ, Gough J. Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation. 1994;57(2):208\u201311.","journal-title":"Transplantation"},{"issue":"12","key":"950_CR3","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1097\/00007890-200206270-00023","volume":"73","author":"JM Gloor","year":"2002","unstructured":"Gloor JM, Cohen AJ, Lager DJ, et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation. 2002;73(12):1965\u20138.","journal-title":"Transplantation"},{"issue":"7","key":"950_CR4","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1097\/01.TP.0000137268.85155.11","volume":"78","author":"F Moreso","year":"2004","unstructured":"Moreso F, Ser\u00f3n D, Carrera M, et al. Baseline immunosuppression is associated with histological findings in early protocol biopsies. Transplantation. 2004;78(7):1064\u20138.","journal-title":"Transplantation"},{"issue":"1","key":"950_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1681\/ASN.2005030249","volume":"17","author":"AT Rowshani","year":"2006","unstructured":"Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol. 2006;17(1):305\u201312.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"950_CR6","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1600-6143.2006.01677.x","volume":"7","author":"M Mengel","year":"2007","unstructured":"Mengel M, Chapman JR, Cosio FG, et al. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am J Transplant. 2007;7(3):512\u20137.","journal-title":"Am J Transplant"},{"issue":"24","key":"950_CR7","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1056\/NEJMoa020009","volume":"349","author":"BJ Nankivell","year":"2003","unstructured":"Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349(24):2326\u201333.","journal-title":"N Engl J Med"},{"issue":"11","key":"950_CR8","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1097\/00007890-199806150-00020","volume":"65","author":"C Legendre","year":"1998","unstructured":"Legendre C, Thervet E, Skhiri H, et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation. 1998;65(11):1506\u20139.","journal-title":"Transplantation"},{"issue":"10","key":"950_CR9","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1111\/j.1600-6143.2005.01050.x","volume":"5","author":"FG Cosio","year":"2005","unstructured":"Cosio FG, Grande P, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant. 2005;5(10):2464\u201372.","journal-title":"Am J Transplant"},{"issue":"9768","key":"950_CR10","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","volume":"377","author":"K Budde","year":"2011","unstructured":"Budde K, Becker T, Arns W, et al. For ZEUS Study Investigators. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377(9768):837\u201347.","journal-title":"Lancet"},{"issue":"1","key":"950_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/ajt.12952","volume":"15","author":"K Budde","year":"2015","unstructured":"Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant. 2015;15(1):119\u201328.","journal-title":"Am J Transplant"},{"key":"950_CR12","doi-asserted-by":"crossref","unstructured":"Budde K, Arns W, Sommerer C, et al. Superior renal function in an everolimus-based calcineurin inhibitor free regimen compared to standard cyclosporine\/mycophenolate and low cyclosporine\/everolimus: follow-up of the HERAKLES study at month 36. Am J Transplant 2014;14(Suppl 3):81 [Abstract 716].","DOI":"10.1097\/00007890-201407151-00252"},{"issue":"5","key":"950_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","volume":"9","author":"Y Lebranchu","year":"2009","unstructured":"Lebranchu Y, Thierry A, Toupance O, et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant. 2009;9(5):1115\u201323.","journal-title":"Am J Transplant"},{"issue":"5","key":"950_CR14","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","volume":"12","author":"L Liefeldt","year":"2012","unstructured":"Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant. 2012;12(5):1192\u20138.","journal-title":"Am J Transplant"},{"issue":"3","key":"950_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","volume":"7","author":"K Solez","year":"2007","unstructured":"Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant. 2007;7(3):518\u201326.","journal-title":"Am J Transplant"},{"issue":"1","key":"950_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/tri.12437","volume":"28","author":"L Mj\u00f6rnstedt","year":"2015","unstructured":"Mj\u00f6rnstedt L, S\u00f8rensen SS, von zur M\u00fchlen B, et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation. Transplant Int. 2015;28(1):42\u201351.","journal-title":"Transplant Int"},{"issue":"4","key":"950_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","volume":"78","author":"BJ Nankivell","year":"2004","unstructured":"Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation. 2004;78(4):557\u201365.","journal-title":"Transplantation"},{"issue":"5","key":"950_CR18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/ajt.13132","volume":"15","author":"L Rostaing","year":"2015","unstructured":"Rostaing L, Hertig A, Albano L, et al. CERTITEM study group. Fibrosis progression according to epithelial-mesenchymal transition profile: a randomized trial of everolimus versus CsA. Am J Transplant. 2015;15(5):1303\u201312.","journal-title":"Am J Transplant"},{"issue":"6","key":"950_CR19","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/00000478-200306000-00012","volume":"27","author":"PN Furness","year":"2003","unstructured":"Furness PN, Taub N, Assmann KJ, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol. 2003;27(6):805\u201310.","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"950_CR20","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1097\/00007890-199511270-00004","volume":"60","author":"N Marcussen","year":"1995","unstructured":"Marcussen N, Olsen TS, Benediktsson H, Racusen L, Solez K. Reproducibility of the Banff classification of renal allograft pathology. Inter- and intraobserver variation. Transplantation. 1995;60(10):1083\u20139.","journal-title":"Transplantation"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0950-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-018-0950-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-018-0950-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T19:06:02Z","timestamp":1561662362000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-018-0950-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1186\/s12882-018-0950-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2018,6,28]]},"assertion":[{"value":"12 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent. The study protocol was approved by the independent ethics committee or institutional review board for each center, and the procedures followed in the trial were in accordance with the Declaration of Helsinki 1975, as revised in 2008.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors give full consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"U Eisenberger has received travel expenses and honoraria from Novartis, TEVA, Astellas and Pfizer;K Budde has received research funds and\/or honoraria from Abbvie, Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Fresenius, Genentech, Hexal, Novartis, Otsuka, Pfizer, Roche, Shire, Siemens, and Veloxis Pharma;F Lehner has received fees and honoraria from Novartis, Astellas, Roche and Sanofi;C Sommerer has received honoraria from Novartis, Chiesi and Sanofi.P Reinke has no conflicts of interest;O Witzke has received research funds and\/or honoraria from Alexion, Astellas, Bristol-Myers Squibb, Chiesi, Janssen-Cilag, MSD, Novartis, Pfizer, Roche and Shire;RP W\u00fcthrich has received fees and honoraria from Astellas, Novartis and Roche;R Stahl has no conflicts of interest;K Heller has no conflicts of interest;B Suwelack has no conflicts of interest;A M\u00fchlfeld has no conflicts of interest;IA Hauser has received honoraria or travel grants from Alexion, Astellas, Chiesi, Fresenius, Hexal, Roche, Novartis, Sanofi, Teva, and has received grant\/research support from Novartis.S Nadalin has no conflicts of interest to declare;M Porstner is an employee of Novartis;W Arns has received study fees and honoraria from Novartis and Astellas.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"154"}}